Salona Global Medical Device (TSE:EVMT) has released an update.
Evome Medical Technologies has reported a significant 100% revenue growth for its Biodex business unit in April 2024 compared to January 2024, driven by a successful reorganization. The company is actively reducing its debt, having cut down various debt categories, and is poised to eliminate acquisition debt with the prospective sale of its non-core unit, DaMar Plastics. Additionally, Biodex is expanding its market presence, notably executing a Term Sheet with a distributor focused on the China market.
For further insights into TSE:EVMT stock, check out TipRanks’ Stock Analysis page.
